BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 2105328)

  • 1. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A; Muruais C; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J; Diaz MJ; Tresguerres JA; Arce V; Lima L
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sexual dimorphism of pyridostigmine potentiation of growth hormone (GH)-releasing hormone-induced GH release in humans.
    Barbarino A; Corsello SM; Tofani A; Sciuto R; Della Casa S; Rota CA; Barini A
    J Clin Endocrinol Metab; 1991 Jul; 73(1):75-8. PubMed ID: 2045474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.
    Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB
    J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E; Cappa M; Casanueva FF; Dieguez C; Ghigo E; Nicolosi M; Valcavi R; Zini M
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
    Giusti M; Marini G; Sessarego P; Peluffo F; Valenti S; Caratti C; Giordano G
    Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.
    Ghigo E; Mazza E; Imperiale E; Rizzi G; Benso L; Müller EE; Camanni F; Massara F
    J Clin Endocrinol Metab; 1987 Sep; 65(3):452-6. PubMed ID: 3114300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E; Goffi S; Arvat E; Nicolosi M; Procopio M; Bellone J; Imperiale E; Mazza E; Baracchi G; Camanni F
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men.
    Coiro V; Volpi R; Bertoni P; Finzi G; Marcato A; Caiazza A; Colla R; Giacalone G; Rossi G; Chiodera P
    Gerontology; 1992; 38(4):217-22. PubMed ID: 1358762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
    Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cholinergic muscarinic pathways on the free fatty acid inhibition of GH responses to GHRH in normal men.
    Peñalva A; Gaztambide S; Vazquez JA; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):171-6. PubMed ID: 2225476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.